Vertex Pharmaceuticals (BSP:VRTX34) Additional Paid-In Capital : R$36,276 Mil(As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Additional Paid-In Capital?

Vertex Pharmaceuticals's quarterly additional paid-in capital increased from Sep. 2023 (R$36,248 Mil) to Dec. 2023 (R$36,502 Mil) but then stayed the same from Dec. 2023 (R$36,502 Mil) to Mar. 2024 (R$36,276 Mil).

Vertex Pharmaceuticals's annual additional paid-in capital declined from Dec. 2021 (R$38,910 Mil) to Dec. 2022 (R$38,745 Mil) and declined from Dec. 2022 (R$38,745 Mil) to Dec. 2023 (R$36,502 Mil).

Vertex Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Vertex Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Additional Paid-In Capital Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

32,579.90

40,612.26

38,910.24

38,745.15

36,502.04

Vertex Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															37,607.13	35,767.40	36,248.08	36,502.04	36,276.35

Vertex Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Vertex Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals (BSP:VRTX34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX:Austria

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals (BSP:VRTX34) Headlines

No Headlines